The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Bosutinib (BOS) versus imatinib (IM) in patients (pts) with chronic phase chronic myeloid leukemia (CP CML) in the BELA trial: 18-month follow-up.
C. Gambacorti-Passerini
Consultant or Advisory Role - Bristol-Myers Squibb; Pfizer
Honoraria - Wyeth
Research Funding - Wyeth
J. E. Cortes
Consultant or Advisory Role - Bristol-Myers Squibb; ChemGenex; Novartis; Pfizer
Research Funding - ARIAD; Bristol-Myers Squibb; ChemGenex; Novartis; Pfizer
D. Kim
Consultant or Advisory Role - Pfizer
Research Funding - Pfizer
H. Kantarjian
Research Funding - Bristol-Myers Squibb; Novartis; Pfizer
N. Khattry
No relevant relationships to disclose
J. H. Lipton
No relevant relationships to disclose
C. Powell
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
P. Harris
Employment or Leadership Position - Pfizer
A. M. Countouriotis
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
T. H. Brummendorf
Consultant or Advisory Role - Bristol-Myers Squibb; Novartis; Pfizer
Honoraria - Bristol-Myers Squibb; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb; Novartis; Pfizer